Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127194 | 0.80 | — | — | |
| SCHEMBL8884479 | 0.77 | — | — | |
| SCHEMBL536868 | 0.77 | — | — | |
| SCHEMBL536879 | 0.73 | — | — | |
| SCHEMBL1025895 | 0.73 | CCNA2 (0.35) | — | |
| SCHEMBL4860847 | 0.69 | CHEK1 (0.36) | — | |
| SCHEMBL1023835 | 0.66 | ADORA2A (0.48) | — | |
| SCHEMBL1022892 | 0.66 | ADORA2A (0.48) | — | |
| SCHEMBL4058597 | 0.65 | — | — | |
| SCHEMBL996665 | 0.63 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | claimed |
| WO-2023167094-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2023-09-07 | — | — | WO | claimed |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-04-20 | — | — | US | claimed |
| EP-4108670-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| EP-4108262-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| CN-115135658-A | Bridged nucleoside and nucleotide using the same | 国立大学法人大阪大学 | 2022-09-30 | — | — | CN | claimed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | claimed |
| WO-2022004388-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2022-01-06 | — | — | WO | claimed |
| EP-3925965-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-22 | — | — | EP | claimed |
| EP-3919501-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-08 | — | — | EP | claimed |
| US-6034087-A | VIRICIDE AGAINST HEPATITIS B | CHONG KUN DANG CORP. (KR) | 2000-03-07 | — | — | US | claimed |
| US-5925756-A | Cyclopropane derivatives and method of preparing the same | AJINOMOTO CO., INC. (JP) | 1999-07-20 | — | — | US | claimed |
| EP-0869953-A1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR PREPARING THEREOF | CHONG KUN DANG CORP (KR) | 1998-10-14 | — | — | EP | claimed |
| US-5777116-A | Cyclopropane derivatives and method of preparing the same | AJINOMOTO CO., INC. (JP) | 1998-07-07 | — | — | US | claimed |
| US-5631259-A | PURINE BASE DERIVATIVES FOR NUCLEOSIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | claimed |
| WO-1996012716-A1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR PREPARING THEREOF | CHONG KUN DANG CORP. (KR) | 1996-05-02 | — | — | WO | claimed |
| EP-0675123-A1 | Cyclopropane derivatives and method of preparing the same | Ajinomoto Co., Inc. (JP) | 1995-10-04 | — | — | EP | claimed |
| US-5151426-A | Treatment of aids | BIOCHEM PHARMA INC. (CA) | 1992-09-29 | — | — | US | claimed |
| EP-0167008-B1 | 1,4:3,6-DIANHYDRO-HEXITE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Heinrich Mack Nachf. (DE) | 1989-09-06 | — | — | EP | claimed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | SLC29A1, SLC29A2, PNP | DPP4 3015/4885CHUK 2656/4885 |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | RNGTT, NUDT1, SLC29A2 | DPP4 2094/4885CHUK 2597/4885 |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | DPP4 1842/4885CHUK 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.